IL-1RA suppresses esophageal cancer cell growth by blocking IL-1α

被引:17
|
作者
Chen, Sui [1 ]
Shen, Zhimin [1 ]
Liu, Zhun [1 ]
Gao, Lei [1 ]
Han, Ziyang [1 ]
Yu, Shaobin [1 ]
Kang, Mingqiang [1 ,2 ,3 ]
机构
[1] Fujian Med Univ, Union Hosp, Dept Thorac Surg, Fuzhou, Fujian, Peoples R China
[2] Fujian Med Univ, Minist Educ, Gastrointestinal Canc, Key Lab, Fuzhou, Fujian, Peoples R China
[3] Fujian Med Univ, Fujian Key Lab Tumor Microbiol, Fuzhou, Fujian, Peoples R China
关键词
esophageal cancer; IL-1RA; VEGF; INTERLEUKIN-1-ALPHA; INFLAMMATION;
D O I
10.1002/jcla.22903
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background Interleukin-1 promotes tumor angiogenesis through VEGF production. The interleukin-1 receptor antagonist can suppress tumors by blocking this effect. Methods Immunohistochemistry, WB, and gene sequencing were used to analyze the expression of IL-1RA in esophageal cancer patients. WB was used to detect the expression of IL-1RA and interleukin-1 alpha in esophageal cancer cells. Stable ESCC cell models overexpressing the IL-1RA were constructed. Their cell functions were tested, and their effects on VEGF were examined. Results IL-1RA is downregulated in primary EC tumors, and this downregulation of IL-1RA is closely related to TNM staging and survival prognosis. The overexpression of IL-1RA increased the proliferation of KYSE410 EC cells, which have a high level of IL-1 alpha expression. Overexpression of IL-1RA in KYSE410 cells promotes a decrease in the expression of VEGF-A. However, IL-1RA expression did not cause any changes in EC9706 cells with low IL-1 alpha expression. Conclusion IL-1RA acts as a tumor suppressor, and its deletion promotes tumor progression by increasing VEGF-A expression in ESCC.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] 脑卒中患者血清IL-1β、IL-1Ra、IL-1Ra/IL-1β比值的监测及临床意义
    唐任光
    韦叶生
    龙显科
    陕西医学杂志, 2005, (04) : 400 - 402
  • [2] 冠心病患者血清IL-1β、IL-1Ra、IL-1Ra/IL-1β比值的监测及临床意义
    李艳
    徐朴
    张平安
    李晓艳
    黄从新
    临床检验杂志, 2004, (02) : 131 - 132
  • [3] Evidence for the biological modulation of IL-1 activity: The role of IL-1Ra
    Dayer, JM
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2002, 20 (05) : S14 - S20
  • [5] Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra
    Muzio, M
    Polentarutti, N
    Facchetti, F
    Peri, G
    Doni, A
    Sironi, M
    Transidico, P
    Salmona, M
    Introna, M
    Mantovani, A
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1999, 29 (03) : 781 - 788
  • [6] IL-1ra versus IL-1 levels in prostatic fluid from prostatitis patients
    Nishimura, T
    Abe, H
    Ito, H
    Ikeda, K
    Oka, F
    Yamamoto, M
    UROLOGIA INTERNATIONALIS, 1998, 60 (02) : 92 - 96
  • [7] Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome
    Rashid, Nadia
    Nigam, Aruna
    Saxena, Pikee
    Jain, S. K.
    Wajid, Saima
    INFLAMMATION RESEARCH, 2017, 66 (07) : 621 - 636
  • [8] THE SYNTHESIS OF IL-1 RECEPTOR ANTAGONIST (IL-1RA) BY SYNOVIAL FIBROBLASTS IS MARKEDLY INCREASED BY THE CYTOKINES TNF-ALPHA AND IL-1
    MARTELPELLETIER, J
    MCCOLLUM, R
    PELLETIER, JP
    BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1175 (03) : 302 - 305
  • [9] Stroke, IL-1ra, IL1RN, Infection and Outcome
    Becker, Kyra J.
    Dankwa, Dorender
    Lee, Richard
    Schulze, Juliane
    Zierath, Dannielle
    Tanzi, Patricia
    Cain, Kevin
    Dressel, Alexander
    Shibata, Dean
    Weinstein, Jonathan
    NEUROCRITICAL CARE, 2014, 21 (01) : 140 - 146
  • [10] Adipose tissue has anti-inflammatory properties - Focus on IL-1 receptor antagonist (IL-1Ra)
    Dayer, Jean-Michel
    Chicheportiche, Rachel
    Yuge-Aubry, Cristiana
    Meier, Christoph
    BASIC AND CLINICAL ASPECTS OF NEUROENDOCRINE IMMUNOLOGY IN RHEUMATIC DISEASES, 2006, 1069 : 444 - 453